Why the study?
Does prolonged amiodarone administration during pregnancy cause adverse effects in mothers with familial dilatative cardiomyopathy and their neonates?
Does prolonged amiodarone administration during pregnancy cause adverse effects in mothers with familial dilatative cardiomyopathy and their neonates?
Prolonged amiodarone use during pregnancy in two patients with familial dilatative cardiomyopathy and ventricular arrhythmias did not result in adverse maternal or neonatal outcomes, including normal thyroid function.
Answers are grounded in this paper and cite their sources.
Supports potential amiodarone safety in select pregnancies; hypothesis-generating case report that should not yet change practice.
Amiodarone treatment in pregnancy might be difficult to handle because of the long half-life of the drug (14-28 days up to 2 months) and because it reduces maternal and neonatal thyroid activity. Although short-term use in pregnancy has been described in cases of fetal supraventricular tachycardia, there are few reports on the chronic use of the drug. In this paper we describe our experience with amiodarone treatment in two pregnant sisters with familial dilatative cardiomyopathy and ventricular malignant extrasystole. Prolonged administration of amiodarone (400-200 mg/die) since the beginning of pregnancy did not have any adverse effects; maternal and neonatal thyroid function was normal, as was the neurological and motor development of the neonates.
No takes yet. Share an insight, caveat, or question.
Valensise et al. (1992) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: